EPS: As of FY2025 Q2, the actual value is USD -1.09.

EBIT: As of FY2025 Q2, the actual value is USD -4.789 M.

Segment Revenue

• Research and Development Expenses: Total R&D expenses were $2.7 million for the three months ended June 30, 2025, an increase of $0.8 million or 43.6% from the three months ended June 30, 2024.

Operational Metrics

• Operating Loss: Operating loss was $4.7 million for the three months ended June 30, 2025, compared to $3.2 million for the same period in 2024, representing an increase of 45.0%.
• Net Loss: Net loss was $4.8 million for the three months ended June 30, 2025, compared to $3.2 million for the same period in 2024, representing an increase of 49.2%.

Cash Flow

• Net Cash Used in Operating Activities: Net cash used in operating activities was $9.5 million for the six months ended June 30, 2025, compared to $10.5 million for the same period in 2024.

Unique Metrics

• Clinical Operations Costs: Clinical operations costs increased due to close-out and analytical activities required for NDA submission related to two Phase 3 studies for CTx-1301.

Future Outlook and Strategy

• Core Business Focus: The company plans to advance commercialization efforts for CTx-1301 into early 2026, requiring approximately $1.5 million of additional capital.
• Non-Core Business: The company is evaluating strategic transactions to acquire or in-license additional products and product candidates to augment its internal development pipeline.